{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:52:00Z","timestamp":1791402720854,"version":"4.3.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03802-1","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:58:21Z","timestamp":1791356301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retifanlimab Versus Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma: A Matching-Adjusted Indirect Comparison Analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-6934","authenticated-orcid":false,"given":"Camilla","family":"Porta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-5251","authenticated-orcid":false,"given":"Gianni","family":"Ghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0666-066X","authenticated-orcid":false,"given":"Massimiliano","family":"Povero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"16","key":"3802_CR1","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.ejca.2015.06.131","volume":"51","author":"C Lebbe","year":"2015","unstructured":"Lebbe C, Becker JC, Grob JJ, et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(16):2396\u2013403.","journal-title":"Eur J Cancer"},{"issue":"6","key":"3802_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/bjd\/ljad404","volume":"190","author":"ST Mohsen","year":"2024","unstructured":"Mohsen ST, Price EL, Chan AW, et al. Incidence, mortality and survival of Merkel cell carcinoma: a systematic review of population-based studies. Br J Dermatol. 2024;190(6):811\u201324.","journal-title":"Br J Dermatol"},{"issue":"3","key":"3802_CR3","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2017.10.028","volume":"78","author":"KG Paulson","year":"2018","unstructured":"Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457-63.e2.","journal-title":"J Am Acad Dermatol"},{"key":"3802_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2022.03.043","volume":"171","author":"ML Gauci","year":"2022","unstructured":"Gauci ML, Aristei C, Becker JC, et al. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline\u2014update 2022. Eur J Cancer. 2022;171:203\u201331.","journal-title":"Eur J Cancer"},{"issue":"4","key":"3802_CR5","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/cam4.2781","volume":"9","author":"CW Lewis","year":"2020","unstructured":"Lewis CW, Qazi J, Hippe DS, et al. Patterns of distant metastases in 215 Merkel cell carcinoma patients: implications for prognosis and surveillance. Cancer Med. 2020;9(4):1374\u201382.","journal-title":"Cancer Med"},{"issue":"9","key":"3802_CR6","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/cam4.815","volume":"5","author":"JG Iyer","year":"2016","unstructured":"Iyer JG, Blom A, Doumani R, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294\u2013301.","journal-title":"Cancer Med"},{"issue":"14","key":"3802_CR7","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2217\/fon-2017-0072","volume":"13","author":"P Nghiem","year":"2017","unstructured":"Nghiem P, Kaufman HL, Bharmal M, Mahnke L, Phatak H, Becker JC. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol. 2017;13(14):1263\u201379.","journal-title":"Future Oncol"},{"issue":"12","key":"3802_CR8","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2589::AID-CNCR15>3.0.CO;2-F","volume":"85","author":"E Voog","year":"1999","unstructured":"Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer. 1999;85(12):2589\u201395.","journal-title":"Cancer"},{"issue":"1","key":"3802_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2326-6066.CIR-13-0034","volume":"1","author":"EJ Lipson","year":"2013","unstructured":"Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54\u201363.","journal-title":"Cancer Immunol Res"},{"key":"3802_CR10","unstructured":"National Cancer Institute. Avelumab becomes first approved treatment for patients with Merkel cell carcinoma 2017. 3 Apr 2017. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2017\/avelumab-fda-merkel-cell."},{"key":"3802_CR11","unstructured":"Bavencio. Prescribing information. EMD Serono, Inc. 2025. https:\/\/www.emdserono.com\/us-en\/pi\/bavencio-pi.pdf. Accessed 24 Apr 2026."},{"key":"3802_CR12","unstructured":"Bavencio. Summary of product characteristics. Merck Serono S.p.A. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bavencio-epar-product-information_en.pdf. Accessed 24 Apr 2026."},{"issue":"6","key":"3802_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100290","volume":"6","author":"SP D'Angelo","year":"2021","unstructured":"D\u2019Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5\u00a0years of follow-up. ESMO Open. 2021;6(6):100290.","journal-title":"ESMO Open"},{"issue":"10","key":"3802_CR14","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase\u00a02 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3802_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002646","volume":"9","author":"SP D'Angelo","year":"2021","unstructured":"D\u2019Angelo SP, Lebb\u00e9 C, Mortier L, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase\u00a0II study. J Immunother Cancer. 2021;9(7):e002646.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3802_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103461","volume":"9","author":"SP D'Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Lebb\u00e9 C, Mortier L, et al. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study. ESMO Open. 2024;9(5):103461.","journal-title":"ESMO Open"},{"key":"3802_CR17","unstructured":"Zynyz. Prescribing information. Incyte Corporation. 2025. https:\/\/www.zynyz.com\/zynyz-prescribing-information. Accessed 24 Apr 2026."},{"issue":"8","key":"3802_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012478","volume":"13","author":"G Grignani","year":"2025","unstructured":"Grignani G, Rutkowski P, Lebb\u00e9 C, et al. Phase\u00a0II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201). J Immunother Cancer. 2025;13(8):e012478.","journal-title":"J Immunother Cancer"},{"key":"3802_CR19","unstructured":"Keytruda. Prescribing information. Merck Sharp & Dohme LLC. 2025. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. Accessed 24 Apr 2026."},{"key":"3802_CR20","doi-asserted-by":"crossref","unstructured":"Cheng D, Ayyagari R, Signorovitch J. The statistical performance of matching-adjusted indirect comparisons: estimating treatment effects with aggregate external control data. Ann Appl Stat. 2020;14(4):1806\u201333.","DOI":"10.1214\/20-AOAS1359"},{"issue":"6","key":"3802_CR21","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"issue":"10","key":"3802_CR22","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935\u201345.","journal-title":"Pharmacoeconomics"},{"key":"3802_CR23","unstructured":"Phillippo DM, Ades T, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. December 2016. 2016. https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf. Accessed 24 Apr 2026."},{"key":"3802_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"3802_CR25","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamadermatol.2023.0061","volume":"159","author":"N Mohsin","year":"2023","unstructured":"Mohsin N, Martin MR, Reed DJ, et al. Differences in Merkel cell carcinoma presentation and outcomes among racial and ethnic groups. JAMA Dermatol. 2023;159(5):536\u201340.","journal-title":"JAMA Dermatol"},{"key":"3802_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1020805","volume":"12","author":"A Yang","year":"2022","unstructured":"Yang A, Wijaya WA, Yang L, He Y, Cen Y, Chen J. The impact of Merkel cell polyomavirus positivity on prognosis of Merkel cell carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:1020805.","journal-title":"Front Oncol"},{"issue":"4","key":"3802_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/120347540000400403","volume":"4","author":"PT Tai","year":"2000","unstructured":"Tai PT, Yu E, Tonita J, Gilchrist J. Merkel cell carcinoma of the skin. J Cutan Med Surg. 2000;4(4):186\u201395.","journal-title":"J Cutan Med Surg"},{"key":"3802_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2018.02.003","volume":"94","author":"A Stang","year":"2018","unstructured":"Stang A, Becker JC, Nghiem P, Ferlay J. The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: an international assessment. Eur J Cancer. 2018;94:47\u201360.","journal-title":"Eur J Cancer"},{"issue":"4","key":"3802_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002478","volume":"9","author":"P Nghiem","year":"2021","unstructured":"Nghiem P, Bhatia S, Lipson EJ, et al. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021;9(4):e002478.","journal-title":"J Immunother Cancer"},{"key":"3802_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2024.110186","volume":"599","author":"Z Li","year":"2024","unstructured":"Li Z, Ji W, Hu Q, Zhu P, Jin Y, Duan G. Current status of Merkel cell carcinoma: epidemiology, pathogenesis and prognostic factors. Virology. 2024;599:110186.","journal-title":"Virology"},{"issue":"11","key":"3802_CR31","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1245\/s10434-016-5266-4","volume":"23","author":"KL Harms","year":"2016","unstructured":"Harms KL, Healy MA, Nghiem P, et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann Surg Oncol. 2016;23(11):3564\u201371.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"3802_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102977","volume":"9","author":"I Lugowska","year":"2024","unstructured":"Lugowska I, Becker JC, Ascierto PA, et al. Merkel-cell carcinoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open. 2024;9(5):102977.","journal-title":"ESMO Open"},{"issue":"9","key":"3802_CR33","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s00432-021-03676-6","volume":"147","author":"M Gu\u00e9nol\u00e9","year":"2021","unstructured":"Gu\u00e9nol\u00e9 M, B\u00e9nigni P, Bourbonne V, et al. The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma. J Cancer Res Clin Oncol. 2021;147(9):2569\u201378.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3802_CR34","unstructured":"Bennett I, Gregory S, Smith R, Birnie R. MAIC. https:\/\/roche.github.io\/MAIC\/index.html. Accessed 24 Apr 2026."},{"key":"3802_CR35","doi-asserted-by":"publisher","unstructured":"Ghetti G, Porta C, Povero M. Retifanlimab vs avelumab in patients with metastatic Merkel cell carcinoma: a cost utility analysis in Italy. Farmecon Health Econ Therap Pathways. 2025. https:\/\/doi.org\/10.7175\/fe.v26i1.1574.","DOI":"10.7175\/fe.v26i1.1574"},{"issue":"5","key":"3802_CR36","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/cam4.2085","volume":"8","author":"R Jain","year":"2019","unstructured":"Jain R, Menzin J, Lachance K, McBee P, Phatak H, Nghiem PT. Travel burden associated with rare cancers: the example of Merkel cell carcinoma. Cancer Med. 2019;8(5):2580\u20136.","journal-title":"Cancer Med"},{"key":"3802_CR37","unstructured":"Member State Coordination Group on Health Technology Assessment. Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons. 2024. https:\/\/health.ec.europa.eu\/document\/download\/4ec8288e-6d15-49c5-a490-d8ad7748578f_en?filename=hta_methodological-guideline_direct-indirect-comparisons_en.pdf."},{"issue":"16 suppl","key":"3802_CR38","volume":"43","author":"M Kearney","year":"2025","unstructured":"Kearney M, Tyroller K, Monfort L, Jangra V, Moradian H. Population-adjusted indirect comparison (PAIC) of avelumab (AVE) and retifanlimab (RETI) in the first-line (1L) treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC). J Clin Oncol. 2025;43(16 suppl):e21513.","journal-title":"J Clin Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03802-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03802-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03802-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:02:37Z","timestamp":1791399757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03802-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":38,"alternative-id":["3802"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03802-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Camilla Porta, Gianni Ghetti, and Massimiliano Povero report employment at AdRes, which have received funding from Incyte Corporation for the conduct of the study.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was based on previously published clinical trials and did not involve any new studies with human participants or animals performed by any of the authors. For the trials included in this analysis (POD1UM-201 trial & JAVELIN Merkel 200 trial), the protocol and amendments were approved by the institutional review board at each participating site and regulatory authorities of participating countries. The trials were conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. All trial participants provided written informed consent.","order":2,"name":"Ethics","label":"Compliance with Ethics Guidelines","group":{"name":"EthicsHeading","label":"Declarations"}}]}}